Pittsburgh, PANCT05905328Now EnrollingIRB Ready

DLBCL Clinical Trial in Pittsburgh, PA

Access cutting-edge dlbcl treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by CytoAgents, Inc.

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions...

Expert Care in Pittsburgh

Access dlbcl specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related dlbcl treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this dlbcl clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This DLBCL Study in Pittsburgh

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed CAR T-cell therapy. The first phase of the study will be open label with dose escalation. Participants will start taking CTO1681 just prior to receiving their CAR T-cell therapy and continue to take the study drug three times daily for a total of 15

Sponsor: CytoAgents, Inc.

Who Can Participate

Inclusion Criteria

Age 18 years or older. 2. Undergone leukapheresis and is scheduled to receive protocol-specified commercially available CD19-directed CAR T-cell therapy (axicabtagene ciloleucel or lisocabtagene maraleucel) for DLBCL without corticosteroid prophylaxis for CRS and/or ICANS. Patients eligible for study must have relapsed or refractory DLBCL after at least one prior line of systemic therapy. 3. Met all inclusion criteria for CAR T-cell therapy per institutional guidelines. 4. Adequate organ function defined as: 1. Estimated Creatinine Clearance per Cockroft Gault formula ≥ 60 mL/min. 2. Serum alanine aminotransferase/aspartate aminotransferase ≤ 2.5 × ULN. 3. Total bilirubin ≤ 1.5 × ULN. 4. Left ventricular ejection fraction ≥ 40% on echocardiogram or multigated acquisition and no clinically significant pericardial effusion. 5. Platelets ≥ 50,000/mm3. 6. Absolute neutrophil count \> 1000/μL. 7. Absolute lymphocyte count \> 100/μL. 5. Documente

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT05905328) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

DLBCL Treatment Options in Pittsburgh, PA

If you're searching for dlbcl treatment options in Pittsburgh, PA, this clinical trial (NCT05905328) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced dlbcl specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all dlbcl clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Pittsburgh, PA

See all lymphoma clinical trials recruiting in Pittsburgh — not just this study.

Browse Lymphoma Trials in Pittsburgh →

Browse More Trials by Condition

Lymphoma TrialsDiffuse Large B-Cell Lymphoma TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA